Pharmacokinetics of Twice or Once Daily DTG (50mg) in Children With HIV and TB

Inclusion Criteria

• •Children \<18 years with confirmed HIV-1 infection weighing 20-35kg ART-naive or experienced, with plans to use DTG for HIV treatment
• •Diagnosis of TB disease with clinician initiating rifampicin-containing first-line therapy
• •Parents/legal guardians/caregivers and children give informed written consent (or assent, where applicable) to be in the study
• •Girls who have reached menses must have a negative pregnancy test at screening and be willing to adhere to two effective methods of contraception (barrier and a non-barrier form of contraception during the study, starting at least 14 days prior to enrolment) if sexually active. The parents/caregivers will be counselled together with the child if the child tests positive in order to reduce any social harm which may arise.